Mesoblast Limited confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9775 AUD | +3.99% |
|
+0.52% | +214.52% |
07-02 | Mesoblast to File Biological License Application with US FDA for Cellular Therapy | MT |
07-01 | Mesoblast to File Biologics License Application for Ryoncil | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+214.52% | 759M | |
+17.72% | 44.44B | |
-10.33% | 37.99B | |
+37.55% | 37.75B | |
+29.36% | 30.78B | |
-8.44% | 27.38B | |
+12.45% | 26.17B | |
+44.19% | 14.15B | |
+31.93% | 12.59B | |
-7.67% | 11.28B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week